- Articles by Topic
- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & Rapid Micro Methods (RMMs)
- Process Analytical Technology (PAT) & Quality by Design (QbD)
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Latest News
- Contact us
Stem Cells - Articles and news items
Ocata Therapeutics licenses induced pluripotent stem cell (iPSC) technology from Allele Biotechnology
Industry news / 24 March 2015 / Victoria White
Ocata has announced that it has entered into a definitive agreement with Allele to access Allele’s proprietary technology for generating human iPSCs…
Promethera Biosciences receives approval in Belgium to enroll patients in the imminent HEP002 Phase IIb/III clinical trial
Industry news / 15 October 2014 / Promethera Biosciences
HEP002 trial represents the world’s first Phase IIb/III trial with a stem cell-based medicinal product for the treatment of urea cycle disorders patients…
Industry news / 10 October 2014 / The Harvard Stem Cell Institute
Giant step toward new diabetes treatment…
New study shows UK public are largely unaware of stem cells as the potential uses are still being realised
Industry news / 9 October 2014 / On Broadcast
18 years since the first cord blood transplants were performed in the UK, public knowledge on this life-saving process is still sorely lacking. A study of over 4,000 people found that nearly a third (32%) of Britons did not know you can store umbilical cord blood and tissue, while the vast majority (85%) agreed there is a lack of awareness…
Featured news / 6 August 2014 / Don Paul Kovarcik, Lonza Walkersville, Inc.
Working in stem cell research can be both immensely rewarding and notoriously difficult. Lonza’s Don Paul Kovarik discusses the challenge of translating new advances in stem cell biology into viable, impactful therapies for patients…
In this free-to-view in-depth focus: Mesenchymal stem cells in cancer therapy – our chance to take charge, and Ovarian cancer stem cells – an essential target for durable remission…
Novartis announces global research collaboration with Regenerex, leveraging a novel cell platform to broaden presence in the cell therapy space
Research collaboration advances company goal to deliver an innovative portfolio of novel cell therapy therapeutics for conditions with a high unmet need…
Complex human brain tissue has been successfully developed in a three-dimensional culture system established in an Austrian laboratory…
The promise held by induced pluripotent stem cells for research and regenerative medicine.
Workshop preview – Cell based assays for screening.
Cardiac stem cells.
Stem Cells Roundtable.
Stem cell therapies: Assuring safety.
Role of pluripotent stem cells in neurotoxicology testing: Impacts and applied innovations.
The Canadian physician William Osler said: “The person who takes medicine must recover twice, once from the disease and once from the medicine.” Indeed, all medicines have side effects – some of which may complicate a patient’s treatment, or in extreme cases may even be fatal. Of concern is the fact that side effects of drugs are often difficult or impossible to predict from preclinical studies, and infamous cases of drugs causing permanent injury or even death of patients in clinical trials illustrate the severity of this problem.
Late stage attrition of drugs is costly for pharmaceutical companies, contributing to the rise of drug prices and delays of drug delivery to market. Better prediction of compound efficacy and safety at early stages of drug development relies on improvement of the models used for pre-clinical testing. The availability of human embryonic stem (hES) cells and, more recently, induced pluripotent stem (iPS) cells may transform the landscape of drug discovery. Here we provide an overview of human pluripotent stem cell features that make them amenable to predictive toxicology and discuss how chemical screens that aim to find drugs that modulate stem cell fates may provide a paradigm for using stem cells in drug discovery.
Genomics, Issue 2 2011 / 19 April 2011 / Janet L. Paluh, Associate Professor Nanobioscience, College of Nanoscale Science and Engineering, University at Albany SUNY and Guohao Dai and Douglas B. Chrisey, Biomedical Engineering, Rensselaer Polytechnic Institute
There is no other biomedical frontier that offers the stunning potential of human pluripotent stem cells and their progenitors in therapeutic applications to ease human suffering or in their ability to provide insights into development and diseases. Cell plasticity for reprogramming has revealed new opportunities in cell-based therapies and informed on lineage specification. What precisely defines each stem cell type or its transit amplifying progenitors that will lead to differentiated adult tissues is still being determined. Challenges remain in cell expansion, directed differentiation and environmental regulation of pluri- and multi-potent cells that avoid unwanted outcomes in transplantation therapies. Traditional culturing methods are giving way to a revolution in tissue engineering and biofabrication. The key to success is a multidisciplinary partnership of biologists, engineers, material scientists and clinicians. This strategy brings together cutting edge technologies and diverse expertise to bridge nano- to micro- to macroscale communication networks. Here, we discuss prominent technologies being applied to engineer the stem cell and tissue niche in vitro for the construction of 3D tissue architectures with integrated vascular networks.
ABB Analytical Measurement Analytik Jena AG Black Swan Analysis Limited CAMO Software AS Cherwell Laboratories Cobalt Light Systems Coulter Partners Enterprise System Partners EUROGENTEC GE Analytical Instruments Hyglos GmbH IDBS IONICON Analytik GmbH Natoli Engineering Company, Inc. ReAgent Thermo Fisher Scientific Vaisala Ltd Waters Corporation WITec GmbH Ytron-Quadro (UK) Limited Yusen Logistics